Use of an innovative syringe pump to deliver bolus rFVIIa for patients with haemophilia and inhibitors undergoing surgery

1. Giangrande PL, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophiliac patients with inhibitors. Haemophilia 2009;15(2): 501-8.10.1111/j.1365-2516.2008.01952.xSearch in Google Scholar

2. Nursing and Midwifery Council. Standards for Medicine Management. 2015. Available from: https://www.nmc.org.uk/globalassets/sitedocuments/standards/nmc-standards-formedicines-management.pdf (accessed 24 November 2016).Search in Google Scholar

3. Lee CA, Kessler CM, Varon D, et al. Safety, efficacy and lessons from continuous infusion with rFVIIa. Haemophilia 1998; 4(4): 564-7.10.1046/j.1365-2516.1998.440564.xOpen DOISearch in Google Scholar

4. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD, et al. Recombinant Factor VIIa Data Collection Group. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8(5): 649-56.10.1046/j.1365-2516.2002.00667.xOpen DOISearch in Google Scholar

5. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.10.1046/j.1365-2141.1997.4463256.xSearch in Google Scholar

6. Monroe DM Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9(Suppl 1): S15-20.Search in Google Scholar

7. Christensen A, Jensen JT, Nøhr AM, Cooper DL. Roomtemperature- stable recombinant activated coagulation factor VII recombinant: chemical and microbiologic stability over 24 hours during continuous in vitro infusion. Clin Ther 2011; 33:1 997-2001.10.1016/j.clinthera.2011.10.023Search in Google Scholar

8. Nedergaard H, Vestergaard S, Theil Jensen P, et al. In vitro Stability of lyophilized and reconstituted recombinant activated factor VII formulated for storage at room temperature. Clin Therapeutics 2008; 30(7): 1309-15.10.1016/S0149-2918(08)80055-0Search in Google Scholar

9. Baudo F, Redaelli R, Caimi TM, et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000; 9: 21-24.10.1016/S0049-3848(00)00220-6Search in Google Scholar

10. NovoSeven [summary of product characteristics]. 2014. Available at: https://www.medicines.org.uk/emc/medicine/21171 (accessed 24 November 2016).Search in Google Scholar